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Abstract 
Background: Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. 
However, the development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral 
artemisinin monotherapies (AMT) predisposes the selection of drug resistant strains. This is particularly a problem 
along the Myanmar/Thailand border. The artemisinin monotherapy replacement programme (AMTR) was established 
in 2012 to remove oral AMT from stocks in Myanmar, specifically by replacing oral AMT with quality-assured ACT 
and conducting behavioural change communication activities to the outlets dispensing anti-malarial medications. 
This study attempts to quantify the characteristics of outlet providers who continue to stock oral AMT despite these 
concerted efforts.
Methods: A cross-sectional survey of all types of private sector outlets that were stocking anti-malarial drugs in 13 
townships of Eastern Myanmar was implemented from July to August 2014. A total of 573 outlets were included. 
Bivariate and multivariable logistic regressions were conducted to assess outlet and provider-level characteristics 
associated with stocking oral AMT.
Results: In total, 2939 outlets in Eastern Myanmar were screened for presence of any anti-malarial drugs in August 
2014. The study found that 573 (19.5 %) had some kind of oral anti-malarial drug in stock at the time of survey and 
among them, 96 (16.8 %) stocked oral AMT. In bivariate analyses, compared to health care facilities, itinerant drug 
vendors, retailers and health workers were less likely to stock oral AMT (33.3 vs 12.9, 10.0, 8.1 %, OR = 0.30, 0.22, 0.18, 
respectively). Providers who cut blister pack or sell partial courses (40.6 vs 11.7 %, OR 5.18, CI 3.18–8.44) and those 
who based their stock decision on consumer demand (32.8 vs 12.1 %, OR 3.54, CI 2.21–5.63) were more likely to stock 
oAMT. Multivariate logistic regressions produced similar significant associations.
Conclusion: Private healthcare facilities and drug shops and providers who prioritize consumers’ demand instead of 
recommended practices were more likely to stock oral AMT. Malaria elimination strategies should include targeted 
interventions to effectively reach those outlets.
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Background
Artemisinin-based combination therapy (ACT) is con-
sidered an essential strategy in global malaria elimina-
tion efforts and the World Health Organization (WHO) 
recommends ACT for treating falciparum malaria all 
over the world [1]. However, emergence of artemisinin 
resistant parasites threatens the progress that has been 
made over the past three decades [2]. There are currently 
few readily available alternative treatments for falci-
parum malaria, which accounts for 70  % of the malaria 
in Myanmar [3]. Widespread availability of oral arte-
misinin monotherapy (oral AMT) and usage of partial, 
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substandard courses predispose the selection of resistant 
parasite strains [2].
The WHO has called for end of marketing and use of 
oral AMT, endorsed in the Sixtieth World Health Assem-
bly in May 2007 [4] and reaffirmed in 2011 with resolu-
tion WHA64.17 [5]. In 2011, global plans for artemisinin 
resistance containment recommended phasing out oral 
AMT, along with three-tiered containment activities [6]. 
This was further intensified as an emergency response 
to artemisinin resistance in Greater Mekong Sub-region 
(GMS) in 2013 [7].
Myanmar plays a critical role in addressing the drug 
resistance malaria problem as it bears the highest bur-
den of malaria among all GMS countries [3]. About 60 % 
of the population (over 30 million people) is living in 
malaria endemic areas [3]. In 2013, more than 350,000 
confirmed malaria cases were reported and this is con-
sidered to be underestimated because it does not include 
cases from the private sector [8]. Following the global 
plan for artemisinin resistance containment, a rapid sup-
ply chain assessment in 2011 found that the most com-
mon type of anti-malarial treatment in private sector 
was two to three tablets of oral AMT [9]. Furthermore, 
a study of private sector outlets in 2012 found that nearly 
70 % of 747 retail outlets stocked oral AMT [10].
As part of a national strategy, in 2012 Population Ser-
vices International (PSI) implemented the artemisinin 
monotherapy replacement project (AMTR) in collabora-
tion with national malaria control program (NMCP) with 
support from Department for International Develop-
ment (DFID) and the Bill and Melinda Gates Foundation 
(BMGF). The key components of the project were (a) dis-
tribution of quality-assured ACT (QAACT) with highly 
subsidized price to replace oral AMT from the private 
sector; (b) dissemination to Myanmar Food and Drug 
Administration to ban the importation of oral AMT at a 
national level; (c) mass media behaviour change commu-
nication (BCC) for demand creation of QAACT with the 
Padonma (lotus) quality seal among end users (through 
TB, radio, billboard); and (d) provider behaviour change 
activity targeting to informal private sector providers and 
outlets in Eastern Myanmar. The first three components 
covered the whole country, while the provider behaviour 
component covered Eastern Myanmar.
However, resource-intensive provider BCC activi-
ties were implemented only in Eastern Myanmar, which 
encompassed high-risk zones of artemisinin resistance 
and surrounding townships [11]. PSI deployed around 
80 field staff called product promoters (PP), who con-
ducted provider BCC via a one-to-one medical detail-
ing approach. PPs provided all the outlet providers in 
their assigned areas with information regarding general 
malaria transmission and prevention, drug resistance 
malaria and key messages around the need to prescribe/
sell full course of QAACT, the risks associated with use 
of oral AMT. They specifically discouraged the stocking 
of oral monotherapy and promoted QAACT.
Moreover, the Myanmar FDA banned the registration 
and importation of oral AMT (oral artesunate in 2011 
and oral artemether in 2012). However, existing stocks 
of previously registered oral AMT could still be distrib-
uted and purchased and prior import licenses before the 
ban still remain legal for 5 years. Moreover, the types of 
outlets stocking and selling oral AMT varies consider-
ably, including the type of outlet, level of training and size 
of outlet, [10]; therefore, it is a considerable challenge 
for effective implementation of resistance containment 
activities. An evaluation of these combined activities 
suggests a dramatic drop of oral AMT availability in the 
private sector from 70  % in 2012 to 35  % in 2013 [12]. 
However, this study did not explore the characteristics of 
outlets that continue to stock oral AMT despite regula-
tions and specific efforts were largely unknown.
It is critical to examine the characteristics of outlets 
that continue to stock oral AMT despite national and 
regional efforts to eliminate the drug. The objective of 
this paper is to use rich data from provider surveys in 
Myanmar to examine the characteristics associated with 
stocking oral AMT, including the type of facility, provider 
knowledge levels and motivations for stocking oral AMT. 
The ultimate aim of these results is to provide evidence 
for targeted interventions in order to phase out oral 
AMT.
Methods
The study was a cross-sectional survey of all types of pri-
vate sector outlets, which were stocking anti-malarial 
drugs in 13 townships of Eastern Myanmar from July to 
August 2014. A total of 573 outlets were included in this 
study. The study area includes all townships where PSI 
product promoters were operating under AMTR pro-
gramme. The study methods were adapted from ACT 
Watch programme [13].
Sampling design
The study employed a two-stage cluster sampling 
approach. In the first stage, from the list of 65 town-
ships under AMTR programme, a sampling frame of 45 
townships was constructed after exclusion of inaccessible 
areas in the armed-conflict zones. From that sampling 
frame, a systematic random sample of 13 townships was 
selected using probability proportionate to population 
size (PPS). For the determination of measure of size for 
PPS, total population residing in each township was used 
as a proxy for the total number of outlets because a com-
prehensive list of all outlets in each area was unavailable.
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In the second stage, a sampling frame of all clusters 
in each selected township was developed. Clusters were 
geographically defined administrative zones, where 3000 
to 5000 people were residing. Clusters in urban areas 
were called wards and in rural areas, village tracts. Next, 
a systematic random sample of six wards and six village 
tracts were selected from each township. In some town-
ships, fewer than six wards were present and all of them 
were selected. The final sampling frame for the second 
stage consisted of 381 wards and 1490 village tracts and 
the final sample comprised 76 wards and 78 village tracts.
Outlets selection and eligibility criteria
Interviewer teams conducted a walk-though census of 
all clusters to map out every private sector outlet, which 
had the potential to stock any drug. Each identified out-
let was screened for presence of any anti-malarial drugs 
using a set of screening questions. All outlets with any 
anti-malarial drug in stock on the day of the survey were 
considered eligible for a full interview.
The types of outlets were classified as the following:
  • Health care facilities (including private hospital, poly 
clinics, general practitioners)
  • Health workers operating in private sector (including 
those in government sector who were practicing in 
private sector in their free hours)
  • Pharmacies and drug shops (this included both regis-
tered pharmacies as well as unregistered drug shops)
  • Itinerant drug vendors and informal providers
  • Small general retail stores
Interview and anti‑malarial drug audit
All eligible outlets were interviewed using paper ques-
tionnaires after obtaining verbal informed consent from 
the provider. A provider was defined as a person who was 
responsible for dispensing the drugs at the outlet. Up to 
three revisits were conducted if a provider was unavail-
able at the time of survey.
The questionnaire consisted of a screening module, a 
full anti-malarial drug audit module and a provider mod-
ule. The screening module consisted of unique identifica-
tion number of each outlet, outlet type and location and 
a set of screening questions for any anti-malarial drugs in 
stock. Anti-malarial drug audit module required obser-
vation of drug packages in addition to the interview. For 
each anti-malarial drug, brand name and generic names, 
active ingredients, strength, package size, pricing and 
stock information were recorded. In the provider module, 
basic demographic characteristics of provider such as age, 
education and qualifications, knowledge on malaria diag-
nosis and treatment as well as recommended treatment 
policies and drug-dispensing practices were included.
Data management, measures and analysis
Data entry from all paper questionnaires including all 
screened outlets was conducted using CSPro data entry 
software, using double data entry [14]. After checking 
and cleaning data using STATA version 12.0, dummy 
variables on outcomes of interest were constructed. 
Oral AMT was defined as any oral anti-malarial drug 
with single active ingredient of artemisinin compound 
without any partner drug, either co-formulated or 
co-packaged.
Demographic characteristics included in the analyses 
included location (rural/urban); outlet type; whether they 
had a license to sell drugs; provider characteristics such 
as education level (low-middle school, high school, grad-
uate) and health qualifications; external support such as 
has someone from PSI ever visited, attended any training, 
heard or seen message about malaria; providers’ knowl-
edge questions; and providers’ practices.
In this study, all outlets, which had any oral anti-
malarial drug at the time of interview, were included 
for final analysis. These outlets were further classified to 
those which had oral AMT versus those which did not. 
This outcome of interest was analysed in relation to the 
characteristics of outlets and their respective provid-
ers. Bivariate logistic regression models used to calcu-
late unadjusted odds ratios. Several multivariate logistic 
regression models were constructed using priori vari-
ables on outlet demographics and results from bivariate 
regression. A final multivariate logistic regression model 
was fitted after consideration for collinearity and analysis 
of deviance via Chi square tests and negative log likeli-
hoods. A minimum p value of 0.05 was used as a cut-off 
for statistical significance and 95  % confidence inter-
vals were calculated. All analyses were conducted on a 
cleaned STATA dataset using R version 3.2.3 in R Studio 
[15].
Ethical considerations
All study participants were over 18 years of age and was 
fully informed of the study and only those who gave their 
consent were interviewed. Verbal informed consent 
was obtained from all study participants. The study was 
reviewed and approved by PSI Research Ethical Board 
(REB) registered under the Office of Human Research 
Protections (OHRP FWA00009154, IRB#00006978).
Results
The research team screened a total of 2939 outlets in 
Eastern Myanmar which had the potential to stock any 
medicine and interviewed the owners/managers of those 
which had any anti-malarial drugs in stock at the time of 
the survey (n = 573, 19.5 %) during the period between 
July and September 2014.
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Table  1 describes the characteristics of outlets that 
stocked anti-malarial drugs. Among the total of 573 out-
lets, 67.7 % were located in rural area and the others were 
in urban area. Across all the outlets, the most common 
types of outlets were health workers (30.0 %) and retail-
ers (27.9  %), followed by pharmacies (21.8  %), itinerant 
drug vendors (10.8 %) and private facilities (9.4 %). Only 
29.5 % had a license to sell drugs. A large proportion of 
providers (43.3 %) had a graduate degree and 56.4 % had 
some kind of health-related qualification, which could 
range from a certificate to a diploma to a degree. The 
majority (79.1  %) answered that someone from PSI had 
ever visited their outlet in the past. However, only 20.9 % 
said they had attended any training or workshop about 
malaria diagnosis and similarly 23.0 % answered that they 
had attended any training or workshop about malaria 
treatment. Over one-third (36.0 %) said they had heard or 
seen any message about malaria.
With respect to provider knowledge, 41.9 % knew the 
most effective treatment for uncomplicated malaria, but 
only 22.9  % knew the government recommended first 
line anti-malarial drug. Additionally, 12.0  % knew that 
some anti-malarial were banned in Myanmar and only 
9.2 % knew the correct meaning of Padonma logo, which 
is the QAACT brand in Myanmar.
In regards to provider practices related to malaria 
treatment, 40.8 % reported that they treated the Plasmo-
dium falciparum and Plasmodium vivax cases differently 
and 45.9 % of the providers mentioned the correct treat-
ment as their most recommended treatment for malaria. 
Two-thirds (66.3 %) of the providers mentioned that they 
usually decided which anti-malarial drugs their custom-
ers received; 17.6 % of providers said that they cut blis-
ter packs or sold partial courses if a customer demanded; 
and 27.1 % admitted that they provided cocktails, which 
meant providing a mix of a variety of drugs. When asked 
how to they decide which drugs to stock, 22.3 % said they 
stocked whichever the consumers demanded; 11.7 % said 
they stocked easily available drugs; and 43.5 % said they 
stocked the most effective drugs.
Table 2 shows outlet characteristics that stock oral AMT 
compared to those that do not in logistic regression models. 
In bivariate analyses, outlet in urban areas were more likely 
to stock oral AMT, compared to those in rural areas (29.2 
vs 10.8  %, OR =  3.40, CI 2.1–5.35). Compared to health 
care facilities, itinerant drug vendors, retailers and health 
workers were less likely to stock oral AMT (33.3 vs 12.9, 
10.0, 8.1 %, OR = 0.30, 0.22, 0.18, respectively). Outlets run 
by an owner/manager with a license to sell drugs were more 
likely to stock oral AMT, compared to those that did not 
(29.0 vs 11.6 %, OR = 3.10, CI 1.98–4.88). Providers with 
graduate education were more likely to stock oral AMT 
compared to those with low-middle level of education (22.2 
Table 1 Characteristics of  anti-malarial stocking outlets 
and their providers in Eastern Myanmar, 2014 (N = 573)
Outlet characteristics Count Percent (%)
Location
 Rural 388 67.7 
 Urban 185 32.3 
Outlet type
 Healthcare facility 54 9.4 
 Pharmacy 125 21.8
 Itinerant drug vendor 62 10.8
 Retailer 160 27.9
 Health worker 172 30.0
License to sell drugs
 Yes 169 29.5
Providers’ characteristics
 Education level
  Low-mid 122 21.3
  High 203 35.4
  Graduate 248 43.3
 Health-related qualification
  Yes 323 56.4
External support
 Had someone from PSI ever visited
  Yes 395 68.9
 Attended any trainings or workshops about malaria diagnosis
  Yes 120 20.9
 Attended any trainings or workshops about malaria treatment
  Yes 132 23.0
 Heard or seen any message about malaria
  Yes 206 36.0
Providers’ knowledge
 Knew the most effective treatment for uncomplicated malaria
  Yes 240 41.9
 Knew the first line anti-malarial recommended by government
  Yes 131 22.9
 Knew that some anti-malarials are banned in Myanmar
  Yes 69 12.0
 Knew the meaning of Padonma logo (QAACT)
  Correct 53 9.2
Providers’ practice
 Treated Pf and Pv differently
  Yes 234 40.8 
 Most recommended treatment for malaria
  Right 263 45.9 
 Decide which anti-malarial medicines customers receive
  Yes 380 66.3 
 Cut blister packs or sell partial courses
  Yes 101 17.6 
 Provided cocktails
  Yes 155 27.1 
 Stock decision made by consumer demand
  Yes 128 22.3 
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vs 9.0 %, OR 2.88, CI 1.50–6.00). Outlets which were visited 
by PSI were found to be less likely to stock oral AMT (13.7 
vs 23.6  %, OR 0.51, CI 0.33–0.81). Those who attended 
any training or workshop on malaria diagnosis were less 
likely to stock oral AMT compared to those who did not 
(8.3 vs 19.0 %, OR 0.39, CI 0.18–0.74 and similar findings 
were among those who attended such training on malaria 
treatment (8.3 vs 19.3 %, OR 0.38, CI 0.19–0.71). Providers 
who knew the most effective treatment for uncomplicated 
malaria were less likely to stock oral AMT compared to 
those who did not (8.8 vs 22.5 %, OR 0.33, CI 0.19–0.54) 
and providers who knew the government recommended 
first-line anti-malarial drug were less likely to stock oral 
AMT (6.9 vs 19.7 %, OR 0.30, CI 0.14–0.59). Providers who 
treated P. falciparum and P. vivax differently were less likely 
to stock oral AMT (12.0 vs 20.1 %, OR 0.54, CI 0.33–0.86); 
those who mentioned correct treatment as their most rec-
ommended treatment for malaria were less likely to stock 
oral AMT (9.9 vs. 22.6  %, OR 0.38, CI 0.23–0.60); those 
who decided which anti-malarial drugs the customers 
received were less likely to stock oral AMT (13.9 vs 22.3 %, 
OR 0.57, CI 0.36–0.89). Providers who cut blister packs or 
sell partial courses (40.6 vs 11.7 %, OR 5.18, CI 3.18–8.44) 
and those who based their stock decision on consumer 
demand (32.8 vs 12.1 %, OR 3.54, CI 2.21–5.63) were more 
likely to stock oral AMT.
Fewer characteristics were independently associated 
with stocking oral AMT when controlling for outlet char-
acteristics in multivariable logistic regression analysis 
(Table  2). Compared to health care facilities, itinerant 
drug vendors, retailers and health workers were less likely 
to stock oral AMT (OR = 0.16, 0.20, 0.18, CI 0.04–0.60, 
0.05–0.77, 0.05–0.59, respectively). Providers who were 
more likely to stock oral AMT were those with health-
related qualifications (OR 3.12, CI 1.45–6.86), those who 
cut blister packs or sold partial courses (OR =  5.17, CI 
2.63–10.41) and those who based their stock decision on 
consumers’ demand (OR = 3.06, CI 1.60–5.92).
Discussion
This study found that compared to health care facilities 
and drug shop/pharmacies, itinerant drug vendors and 
health workers were five times less likely to stock oral 
AMT. These findings are corroborated by previous data 
in Eastern Myanmar in 2012, where 43 % of health care 
facilities stocked oral AMT while only 20  % of health 
workers and 29 % of itinerant drug vendors did so [10]. A 
potential explanation for these findings may be that oral 
AMT is stocked in these facilities in order to provide a 
range of options for consumers, even if they are banned 
or no longer recommended for routine use. This hypoth-
esis is supported in the current study by the three-fold 
increased odds of stocking oral AMT if decisions are 
reportedly driven by consumer demand and also the five-
fold increased odds of stocking oral AMT among provid-
ers who cut blister packs or sold partial courses. Overall, 
this study found that one-third of health facilities still 
stock oral artemisinin monotherapy despite concerted 
national efforts to ban them. This is much higher than, 
for example, in Cambodia, where the availability of oral 
AMT among private-for-profit health facilities was 0.6 % 
in 2013 [16].
Contrary to expectations, retailers were five times less 
likely to stock oral AMT compared to healthcare facili-
ties. In this study, only one in ten retailers stocked oral 
monotherapy. This is lower than the previous studies in 
2012, which found that 77 % of general retailers stocked 
oral AMT [10]. One potential explanation is that there 
have been significant efforts to address quality issues 
among retailers. For example, PSI product promoters 
have specifically targeted retail outlets since 2012 with 
behavioural change communication activities and the 
promotion of QAACT in Eastern Myanmar [17]. Past 
studies have found that availability and market share of 
oral AMT declined rapidly in Eastern Myanmar where 
PSI intervention activities were particularly focused on 
certain types of outlets including retailers [17]. These 
findings suggest that expanding this intervention to dif-
ferent types and larger facilities may be beneficial in elim-
inating oral AMT stock.
An additional unexpected finding is that that those 
who had higher health-related qualifications were 
approximately three times more likely to stock oral AMT 
in multivariable analyses adjusting for other factors. An 
explanation for this is that higher health-related qualifica-
tions may reflect general private practitioners who stock 
oral monotherapy because there have been no targeted 
efforts specifically among general practitioners. As stated 
earlier, PSI product promoters have specifically worked 
with retail outlets and lower-level providers. These find-
ings suggest that targeted training will be needed for all 
providers. This underscores the fact that qualifications do 
not always lead to the recommended practices. Because 
guidelines and drug treatments are constantly changing, 
staying up-to-date on protocols is particularly important 
for malaria endemic areas.
Table 1 continued
Outlet characteristics Count Percent (%)
 Stock decision made by easily available
  Yes 67 11.7 
 Stock decision made by more effective
  Yes 249 43.5 
Pf, Plasmodium falciparum; Pv, Plasmodium vivax
Page 6 of 8Thein et al. Malar J  (2016) 15:334 
Table 2 Difference between  the outlets that  stocked oral AMT and  those that  stocked other anti-malarial—bivariate 
and multivariate correlates
Outlet characteristics Outlets that stocked oral AMT OR 95 % CI p‑value AOR 95 % CI p‑value
No (N = 477) Yes (N = 96)
Count Percent Count Percent
Location
 Rural 346 89.2 42 10.8 
 Urban 131 70.8 54 29.2 3.40 2.17−5.35 0.000 1.50 0.74−3.06 0.260
Outlet type
 Private facility 36 66.7 18 33.3 
 Pharmacy 85 68.0 40 32.0 0.94 0.48−1.88 0.861 0.40 0.14−1.1 0.076
 Itinerant drug vendor 54 87.1 8 12.9 0.30 0.11−0.73 0.011 0.16 0.04−0.6 0.008
 Retailer 144 90.0 16 10.0 0.22 0.10−0.48 0.000 0.20 0.05−0.77 0.020
 Health worker 158 91.9 14 8.1 0.18 0.08−0.39 0.000 0.18 0.05−0.59 0.005
License to sell drugs
 Yes 120 71.0 49 29.0 3.10 1.98−4.88 0.000 1.58 0.74−3.43 0.240
Providers’ characteristics
 Education
  Low-mid 111 91.0 11 9.0 
  High 173 85.2 30 14.8 1.75 0.87−3.78 0.133 1.28 0.53−3.21 0.589
  Graduate 193 77.8 55 22.2 2.88 1.50−6.00 0.003 0.96 0.36−2.58 0.928
Health-related qualification
 Yes 265 82.0 58 18.0 1.22 0.78−1.92 0.381 3.12 1.45−6.86 0.004
External support
 Had someone from PSI ever visited
  Yes 341 86.3 54 13.7 0.51 0.33−0.81 0.004 0.72 0.4−1.3 0.273
 Attended any trainings or workshops about malaria diagnosis
  Yes 110 91.7 10 8.3 0.39 0.18−0.74 0.007 0.78 0.18−3.35 0.733
 Attended any trainings or workshops about malaria treatment
  Yes 121 91.7 11 8.3 0.38 0.19−0.71 0.004 1.41 0.31−6.09 0.651
 Heard or seen any message about malaria
  Yes 174 84.5 32 15.5 0.87 0.54−1.37 0.558 0.90 0.5−1.6 0.726
Providers’ knowledge
 Knew the most effective treatment for uncomplicated malaria
  Right 219 91.2 21 8.8 0.33 0.19−0.54 0.000 0.67 0.24−1.95 0.457
 Knew the first line anti-malarial recommended by government
  Right 122 93.1 9 6.9 0.30 0.14−0.59 0.001 0.49 0.19−1.16 0.116
 Knew that some anti-malarials are banned in Myanmar
  Yes 60 87.0 9 13.0 0.72 0.32−1.44 0.381 0.72 0.29−1.7 0.475
 Knew the meaning of Padonma logo (QAACT)
  Correct answer 49 92.5 4 7.5 0.38 0.11−0.96 0.069 0.45 0.12−1.38 0.194
Providers’ practice
 Treated Pf and Pv differently
  Yes 206 88.0 28 12.0 0.54 0.33−0.86 0.012 0.59 0.28−1.2 0.148
 Most recommended treatment for malaria
  Right 237 90.1 26 9.9 0.38 0.23−0.60 0.000 0.66 0.24−1.76 0.422
 Decide which anti-malarial medicines customers receive
  Yes 327 86.1 53 13.9 0.57 0.36−0.89 0.012 1.12 0.52−2.39 0.772
 Cut blister packs or sell partial courses
  Yes 60 59.4 41 40.6 5.18 3.18−8.44 0.000 5.17 2.63−10.41 0.000
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There are limitations in this study. For example, we were 
unable to conduct stratified analyses on each outlet type 
as it would decrease the statistical power in the analy-
ses. Another limitation was that the study was conducted 
in the townships in Eastern Myanmar where there were 
substantial efforts to address malaria, including intensive 
BCC activities conducted by PSI Myanmar Product Pro-
moters. Therefore, the observed behaviours may not be 
generalizable in areas where there were no such activi-
ties, especially concerning the retailers. These findings are 
particularly helpful, however, to understand which outlets 
and providers continue to stock monotherapy, even after 
significant resources and efforts have been made.
Regardless of the limitations, a number of recommen-
dations can be made. The study found consistently that 
outlets which prioritized the consumer demand instead 
of recommended good practices were more likely to stock 
oral AMT. Future programs should target all providers, 
including specific training for best practices and drug 
treatments for malaria. As only about one-third of pro-
viders had any exposure on messages related to malaria 
and only 12 % knew that some anti-malarial drugs were 
banned, there is still a lot of room for dissemination of 
these interventions and their enforcement. Targeted, 
reinforced BCC messages, reorientation of focus of inter-
vention to include facilities and pharmacies and support 
and enforcement from FDA and ministry of health could 
all help in achieving the aim of phasing out oral AMT in 
the future, with wider benefits in reducing artemisinin 
resistance and malaria elimination.
Conclusions
Private healthcare facilities and drug shop/pharmacies 
and providers who prioritize consumers’ demand instead 
of recommended practices were more likely to stock oral 
AMT. Malaria elimination strategies should include tar-
geted interventions to effectively reach those outlets.
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